stella
beta
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma — Stella
Recruiting
Back to Pancreatic Ductal Adenocarcinoma (PDAC) trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Peking University Shenzhen Hospital, Shenzhen, Guangdong
View full record on ClinicalTrials.gov